Identification of a Novel Sulfonamide Non-Nucleoside Reverse Transcriptase Inhibitor by a Phenotypic HIV-1 Full Replication Assay

PLoS ONE

Volumn 8, Issue 7, 2013, Pages

  Kim, Tae Hee ^a,b   Ko, Yoonae ^a   Christophe, Thierry ^a   Cechetto, Jonathan ^a   Kim, Junwon ^a   Kim, Kyoung Ae ^a   Boese, Annette S ^a   Garcia, Jean Michel ^a   Fenistein, Denis ^a   Ju, Moon Kyeong ^a   Kim, Junghwan ^a   Han, Sung Jun ^a   Kwon, Ho Jeong ^b   Brondani, Vincent ^a   Sommer, Peter ^a  

^a Institute Pasteur Korea   (South Korea)

^b Yonsei University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

FLOXURIDINE; FLUOROURIDINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; RNA DIRECTED DNA POLYMERASE; SULFONAMIDE;

ANTIVIRAL ACTIVITY; ARTICLE; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DRUG PROTEIN BINDING; DRUG STRUCTURE; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; MICROTUBULE ASSEMBLY; MOLECULAR DOCKING; PHENOTYPE; POINT MUTATION; PROMOTER REGION; VIRUS REPLICATION; VIRUS STRAIN;

ANTIVIRAL AGENTS; CELL LINE; CELL SURVIVAL; DRUG DISCOVERY; DRUG EVALUATION, PRECLINICAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; HIGH-THROUGHPUT SCREENING ASSAYS; HIV-1; HUMANS; MODELS, BIOLOGICAL; PROTEIN BINDING; RNA-DIRECTED DNA POLYMERASE; SMALL MOLECULE LIBRARIES; SULFONAMIDES; VIRUS REPLICATION;

EID: 84880402335     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0068767     Document Type: Article

References (29)

1. Masur H, Michelis MA, Greene JB, Onorato I, Stouwe RA, et al. (1981) An outbreak of community-acquired Pneumocystis carinii pneumonia: initial manifestation of cellular immune dysfunction. N Engl J Med. 305(24): 1431-8.
2. Joint United Nations Programme on HIV/AIDS (UNAIDS) (2011) World AIDS Day Report. ISBN: 978-92-9173-904-2 {pipe} UNAIDS/JC2216E.
3. Flexner C, (2007) HIV drug development: the next 25 years. Nat Rev Drug Discov. 6(12): 959-66.
4. Simon V, Ho DD, Abdool Karim Q, (2006) HIV/AIDS epidemiology, pathogenesis, prevention, and treatment. Lancet. 368(9534): 489-504.
5. Little SJ, Holte S, Routy JP, Daar ES, Markowitz M, et al. (2002) Antiretroviral-drug resistance among patients recently infected with HIV. N Engl J Med. 347(6): 385-94.
6. Wensing AM, Boucher CA, (2003) Worldwide transmission of drug-resistant HIV. AIDS Rev. 5(3): 140-55.
7. Daar ES, Richman DD, (2005) Confronting the emergence of drug-resistant HIV type 1 impact of antiretroviral therapy on individual and population resistance. AIDS Res Hum Retorviruses. 21(5): 343-57.
8. Richman DD, Margolis DM, Dalaney M, Greene WC, Hazuda D, et al. (2009) The challenge of finding a cure for HIV infection. Science 323(5919): 1304-7.
9. Carr A, Amin J (2009) Efficacy and tolerability of initial antiretroviral therapy: a systematic review. Aids, 23(3): 343-53; discussion 355-6.
10. Chiao SK, Romero DL, Johnson DE, (2009) Current HIV therapeutics: mechanistic and chemical determinants of toxicity. Curr Opin Drug Discov Devel. 12(1): 53-60.
11. Westby M, Nakayama GR, Butler SL, Blair WS, (2005) Cell-based and biochemical screening approaches for the discovery of novel HIV-1 inhibitors. Antiviral Res. 67(3): 121-40.
12. Boese A, Sommer P, Gaussin A, Reimann A, Nehrbass U, (2004) Ini1/hSNF5 is dispensable for retrovirus-induced cytoplasmic accumulation of PML and does not interfere with integration. FEBS Lett. 578(3): 291-296.
13. Sommer P, Vartanian JP, Wachsmuth M, Henry M, Guetard D, et al. (2004) Anti-termination by SIV Tat requires flexibility of the nascent TAR structure. J Mol Biol. 344(1): 11-28.
14. Reed LJ, Muench H, (1938) A simple method of estimating fifty percent endpoints. Am. J. Hyg. 27: 493-497.
15. Zhang JH, Chung TD, Oldenburg KR, (1999) A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays. J Biomol Screen. 4(2): 67-73.
16. Petropoulos CJ, Parkin NT, Limoli KL, Lie YS, Wrin T, et al. (2000) A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1. Antimicrob Agents Chemother. 44(4): 920-8.
17. Berman HM, Westbrook Z, Feng Z, Gilliland G, Bhat TN, et al. (2000) The Protein Data Bank. Nucleic Acids Research. 28(1): 235-242.
18. Kertesz DJ, Brontherton-Pleiss C, Yang M, Wang Z, Lin X, et al. (2010) Discovery of piperidin-4-yl-aminopyrimidines as HIV-1 reverse transcriptase inhibitors. N-benzyl derivatives with broad potency against resistant mutant viruses. Bioorg. Med. Chem. Lett. 20(14): 4215-4218.
19. Lansdon EB, Brendza KM, Hung M, Wang R, Mukund S, et al. (2010) Crystal structures of HIV-1 reverse transcriptase with etravirine (TMC125) and rilpivirine (TMC278): implications for drug design. J. Med. Chem. 53(10): 4295-4299.
20. Tucker TJ, Sisko JT, Tynebor RM, Williams TM, Felock PJ, et al. (2008) Discovery of 3-{5-[(6-amino-1H-pyrazolo[3,4-b]pyridine-3-yl)methoxy]-2-chlorophenoxy}-5-chlorobenzonitrile (MK-4965): a potent, orally bioavailable HIV-1 non-nucleoside reverse transcriptase inhibitor with improved potency against key mutant viruses. J. Med. Chem. 51(20): 6503-6511.
21. Protein Preparation Wizard, Schrödinger Suite 2011 Protein Preparation Wizard; Epik version 2.3, Schrödinger, LLC, New York, NY, 2012; Impact version 5.8, Schrödinger, LLC, New York, NY, 2012; Prime version 3.1, Schrödinger, LLC, New York, NY, 2012.
22. Glide (2012) version 5.8, Schrödinger, LLC, New York, NY.
23. MacroModel (2012) version 9.9, Schrödinger, LLC, New York, NY.
24. Rosenblum LL, Patton G, Grigg AR, Frater AJ, Cain D, et al. (2001) Differential susceptibility of retroviruses to nucleoside analogues. Antivir Chem Chemother. 12(2): 91-7.
25. DAS k, Bauman JD, Clark A, Frenkel YV, Lewi PJ, et al. (2008) High-resolution structures of HIV-1 reverse transcriptase/TMS278 complexes: strategic flexibility explains potency against resistance mutations. Poc Natl Acad Sci U S A. 105(5): 1466-71.
26. Merrill DP, Manion DJ, Chou TC, Hirsch MS, (1997) Antagonism between human immunodeficiency virus type 1 protease inhibitors indanavir and saquinavir in vitro. J Infect Dis 176(1): 265-8.
27. McMahon JB, Gulakowski RJ, Weislow OS, Schultz RJ, Narayanan VL, et al. (1993) Diarylsulfones, a new chemical class of nonnucleoside antiviral inhibitors of human immunodeficiency virus type 1 reverse transcriptase. Antimicrob Agents Chemother. 37(4): 754-60.
28. Masuda N, Yamamoto O, Fujii M, Ohgami T, Fujuyasu J, et al. (2004) Studies of non-nucleoside HIV-1 reverse transcriptase inhibitors. Part 1: Design and synthesis of thiazolidenebenzenesulfonamides. Bioorg Med Chem. 12(23): 6171-82.
29. Masuda N, Yamamoto O, Fujii M, Ohgami T, Fujiyasu J, et al. (2005) Studies of non-nucleoside HIV-1 reverse transcriptase inhibitors. Part 2: Synthesis and structure-activity relationships of 2-cyano and 2-hydroxy thiazolidenebenzenesulfonamide derivatives. Bioorg Med Chem. 13(4): 949-961.